Oncodesign Precision Medicine Société anonyme (EPA: ALOPM)

EPA: ALOPM Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Operating Revenue	0.8	1.4	8.02
Other Revenue	0.54	0.34	0.27
Revenue	1.34	1.74	8.29
Revenue Growth (YoY)	-	-79.02%	-
Cost of Revenue	7.3	8	7.56
Gross Profit	-5.96	-6.26	0.73
Selling, General & Admin	2.91	3.31	2.08
Other Operating Expenses	0.12	0.12	0.1
Operating Expenses	3.29	3.69	2.34
Operating Income	-9.24	-9.94	-1.61
Interest Expense	-0.25	-0.15	-0.12
Interest & Investment Income	0.14	0.24	0
Currency Exchange Gain (Loss)	-0.02	-0.02	0
Other Non Operating Income (Expenses)	-0.1	-	0
EBT Excluding Unusual Items	-9.46	-9.86	-1.72
Gain (Loss) on Sale of Investments	0.01	0.01	-
Other Unusual Items	0	0	-0
Pretax Income	-9.45	-9.85	-1.72
Income Tax Expense	-1.66	-1.76	-1.49
Net Income	-7.79	-8.09	-0.23
Net Income to Common	-7.79	-8.09	-0.23
Shares Outstanding (Basic)	-	17	-
Shares Outstanding (Diluted)	-	17	-
EPS (Basic)	-	-0.49	-
EPS (Diluted)	-	-0.49	-
Gross Margin	-	-	8.84%
Operating Margin	-689.94%	-571.55%	-19.41%
Profit Margin	-581.49%	-465.04%	-2.79%
EBITDA	-8.99	-9.69	-1.45
EBITDA Margin	-	-	-17.43%
D&A For EBITDA	0.25	0.25	0.16
EBIT	-9.24	-9.94	-1.61
EBIT Margin	-	-	-19.41%
Revenue as Reported	1.25	1.75	8.32

Source: S&P Capital IQ. Standard template. Financial Sources.